If you are thinking about buying a smart scale, it doesn’t get any better than Withings scales. The company has made a name for itself in this product category, and other brands have some catching up to do. This site has published a number of reviews of its products, most recently the Body Scan. So make sure to check these out.

The range now has five clear steps

The range now spans a number of different scales, at different price points.

Body Smart remains the entry point. It covers more than 20 biomarkers, uses two bioimpedance frequencies up to 100 kHz and sticks to single-zone body composition. That means fat and muscle mass, hydration level, visceral fat, BMI, basal metabolic rate and standing heart rate. For most people who want a smarter version of a normal scale, this is the basic Withings pitch.

Body Comp moves things along without adding a handle. It raises the count to more than 30 biomarkers and adds vascular age plus a Nerve Health Score. Withings describes this as detecting early signs of diabetes-related complications, so this model sits closer to a health check-up than a fitness scale. It still uses two frequencies up to 100 kHz and single-zone body composition, so the upgrade is more about health signals than body mapping.

BodyFit is the interesting middle option

BodyFit is the new model that could cause the most confusion. It costs $279.95 in the US and jumps to more than 40 biomarkers, but the real shift is the retractable handle. That enables 6-zone analysis across the body rather than one averaged reading from the feet.

It also uses 13 bioimpedance frequencies up to 800 kHz, which puts it ahead of the original Body Scan on that specific line in the table. But BodyFit does not have ECG, atrial fibrillation detection or Nerve Response Score, so it is not a full health station. It might fit in the sweet spot for someone mainly interested in body composition, fat and muscle distribution, visceral fat and vascular age.

Body Scan still has a role

The original Body Scan remains the first proper health station in the lineup. It includes more than 40 biomarkers, 6-zone body composition, a retractable handle, standing heart rate, vascular age, 6-lead ECG and atrial fibrillation detection. It also adds Nerve Response Score, with stress response and recovery insights.

That makes Body Scan a different product from BodyFit, even though BodyFit looks strong on body composition. Body Scan leans harder into cardiovascular and nerve health. The comparison sheet also shows Glucose Resilience as a new metabolic feature for Body Scan, though this is one of those areas where buyers should watch the app rollout and Withings+ requirements closely.

BodyScan 2 is the top model, but not a simple upgrade for everyone

BodyScan 2 pushes the range to more than 60 biomarkers. It uses 13 bioimpedance frequencies up to 800 kHz, keeps 6-zone analysis and adds improved segmental measurements. The handle also gets touch-sensor electrodes, a built-in display and improved readability, which should make daily use less awkward than reading everything from the scale platform.

The extra health features are the bigger story. BodyScan 2 adds blood pressure insights, Heart Age and blood oxygen levels. It also keeps vascular age, 6-lead ECG, atrial fibrillation detection and Nerve Response Score. On paper, all of this sounds great – if you’re into that level of detail.

The subscription piece needs watching

What needs watching is the Withings+ subscription. It now sits across the range, but not every model gets the same experience. The comparison sheet shows Body Smart, Body Comp and BodyFit with Personalized Health Priorities, Weekly Plan and BodyPath. Body Scan and BodyScan 2 go further with cardiologist review included and Longevity Intelligence.

This is where the buying decision becomes less clean. Heart Age and Glucose Resilience sound like headline features for BodyScan 2, but Withings says those sit behind Withings+. So the question is not only which scale has the sensor hardware. It is also which insights remain useful without paying for the extra software layer.

Which one makes the most sense

Body Smart remains the sensible entry model if weight, body composition and basic health trends are enough. Body Comp adds useful health markers without the larger handle-based design, so it fits buyers who want vascular age and nerve health but do not care about segmental body mapping.

BodyFit looks like the best fit for people who mainly want better body composition data. It brings the handle, 6-zone analysis and 13-frequency bioimpedance at a much lower price than BodyScan 2. Body Scan remains the better choice if ECG and nerve response are important, especially if it gets discounted now that BodyScan 2 has arrived.

BodyScan 2 is the one for buyers who want the newest Withings health platform and are comfortable with the subscription angle. It has the broadest mix of body composition, cardiovascular, metabolic and longevity-style metrics. But the arrival of the new model also makes the cheaper options look more interesting, because the range now has clearer tiers than the product names suggest.

The post Which Withings scale should you buy in 2026 appeared first on Gadgets & Wearables.

The launch follows the BodyScan 2 Insider Program from May. This gave 500 European users early access to final production hardware.

Withings leans hard into longevity

Withings is calling BodyScan 2 its first science-backed longevity station. That is a big label, but the idea is simple enough. The scale tries to turn a daily weigh-in into a broader cardiometabolic check.

It measures more than 60 biomarkers over time and pulls key signals into Longevity Intelligence inside the Withings app. That is meant to act as a health cockpit, showing how your body is trending rather than just displaying isolated readings.

The main features include 6-zone body composition, metabolic assessment, complete heart health and Longevity Intelligence. It still looks like a smart scale, but Withings clearly wants it to sit closer to a home health monitor than a weight tracker.

Body composition is the easy sell

The 6-zone body composition feature will probably be the most useful part for many buyers. Instead of giving one whole-body estimate, BodyScan 2 breaks fat and muscle readings down across different body zones.

That should make progress easier to understand. Weight alone does not say much when someone is building muscle, losing fat or trying to avoid lean mass loss. A more detailed breakdown gives users something more practical to track.

As always with home body composition scales, the exact number should not be treated as lab-grade truth. The value is in regular readings under similar conditions and watching the trend over time.

Metabolic tracking is where it gets more ambitious

The metabolic side is more interesting, although part of it is not ready yet. Withings says BodyScan 2 can track visceral fat, calorie balance and Glucose Resilience, but Glucose Resilience is marked as coming soon.

Now make no mistake, BodyScan 2 is not a continuous glucose monitor. And it is not directly measuring blood sugar. This looks more like a broader metabolic score built from the data Withings can collect or model through its app.

BodyScan 2 also brings in several cardiovascular features. Withings lists AFib detection, vascular age, blood oxygen, cardiac efficiency and hypertension notifications.

The scale is not cheap and some of the more interesting features are tied to Withings+. Heart Age is one example. It turns cardiac timing and efficiency data into an age-style score, which may be easier for users to understand than raw numbers.

Europe first, US next

BodyScan 2 is available now in Europe through the Withings website. In the UK it is priced at £450.

The US launch should follow next week. The company also says the white version is not available yet, but should arrive before the end of summer.

The post Withings BodyScan 2 arrives in Europe as US launch nears appeared first on Gadgets & Wearables.

This is the part most scales get wrong

Most smart scales still work the same way. You step on them barefoot, they send a signal through your lower body, and then software makes its best guess about the rest. It is useful, but only to a point.

BodyFit tries to do something more serious. The retractable handle lets the current travel through the full body, including the upper half, so the scale can track each limb and your trunk independently. That is a much better way to spot muscle imbalances, uneven fat loss or recovery issues after injury.

Withings says the system reaches 99% correlation with DEXA scans for fat mass results, which is about as strong a marketing claim as you can make in this category. It uses multifrequency BIS technology with eight electrodes and 13 frequencies up to 800 kHz, so this is clearly built to be more than a casual wellness gadget.

The scale also tracks things like visceral fat, basal metabolic rate, vascular age, pulse wave velocity and standing heart rate. The full scan takes about 20 seconds, so it is still quick enough for everyday use and not something that feels like a chore.

Where it sits next to Body Scan 2

This launch is more interesting because Withings has also been talking about Body Scan 2. This device picked up a CES 2026 Innovation Award and is positioned as the company’s cardiometabolic flagship.

That device goes much further than body composition. It is built around heart health, cardiovascular risk and long-term longevity tracking, with Withings describing it more like a checkup machine for your bathroom. It is meant to give users a broader picture of where their health is heading, not just whether their latest training block is working.

I found the same with the original Body Scan when I reviewed it. It felt less like a scale and more like a full health station. The retractable handle was a big part of that, helping it deliver much richer data than a standard smart scale.

BodyFit takes a similar but simpler route. It keeps the segmental body composition side of things, but leaves out the more medical-style focus and long-term cardiovascular checks.

US first, Europe next

The first batch is now rolling out to the US. Those living there can buy the scale. Europe should follow soon.

The company specifically points to the rapid growth of GLP-1 use in the US as one reason for that priority. That makes sense. As more people use GLP-1 medications for weight loss, there is more interest in tracking what is actually being lost. Weight alone does not tell you much if muscle mass is dropping too fast. A scale that can separate fat loss from muscle loss becomes a lot more useful in that situation.

That may end up being the strongest reason BodyFit exists at all. It is not trying to be the fanciest scale Withings has ever made. It is trying to be the one many people will want to buy.

Check it out on the company’s website.

Subscribe to our monthly newsletter! Check out our YouTube channel.

And of course, you can follow Gadgets & Wearables on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.

The post Withings BodyFit goes on sale in the US with segmental body metrics appeared first on Gadgets & Wearables.

The lawsuit is listed as Maurer v. Garmin International, Inc. et al, case number 1:26-cv-06389, in the U.S. District Court for the Northern District of Illinois. It was filed on May 29, 2026 by Victor Maurer, with Garmin International named among the defendants. The docket lists it as an “Other Fraud” case, with a jury demand and a 56-page complaint.

At this stage, this is still an allegation. Garmin has not yet had its say in court, and a proposed class action is not the same as a finding that the company did anything wrong.

What the lawsuit claims

The complaint focuses on the Garmin Index S2 Smart Scale, so the latest version of its smart scale. The issue is the body composition side.

According to the complaint, Garmin “failed to disclose” key information about the scale’s alleged inability to accurately measure body composition. The plaintiff is seeking monetary damages and a declaration that the Garmin smart scale cannot accurately measure body composition.

The wording used in the lawsuit is pretty direct. It claims that the foot-to-foot bioelectrical impedance technology in the scale is “incapable of accurate body composition measurements,” making Garmin’s representations allegedly false, misleading and deceptive to consumers.

That is the heart of the case. The plaintiff is not simply saying smart scale readings vary from day to day. He is arguing that the technology Garmin uses does not support the accuracy message attached to the product.

The problem with foot-to-foot BIA

The Index S2 uses bioelectrical impedance analysis, often shortened to BIA. This works by sending a small electrical signal through the body and measuring resistance. From there, the scale estimates body water, fat mass, muscle mass and other values.

The lawsuit argues that foot-to-foot BIA has a basic limitation. Because the user stands barefoot on the scale, the signal travels through the lower body rather than the whole body. That can make the estimate less representative of total body composition, especially when compared with more advanced methods.

The complaint reportedly cites a 2021 JMIR mHealth and uHealth study that compared three foot-to-foot smart scales with DEXA. According to the filing, those smart scales underestimated both fat mass and muscle mass by as much as around 8kg, or up to 8 percentage points!

Garmin’s accuracy language is the key issue

The legal question will probably come down to marketing language. Smart scales can be useful for trends, especially if someone weighs themselves under similar conditions each time. But there is a big difference between trend tracking and presenting body composition numbers as accurate measurements.

The lawsuit points to Garmin and retailer descriptions. Garmin’s own product page uses the phrase “Accuracy matters when it comes to your goals.” The complaint also references an Amazon listing that tells buyers they can get accurate measurements for weight, weight trend, body fat percentage, BMI, skeletal muscle mass and more.

Garmin may argue that consumer smart scales provide estimates and that users understand these are not clinical-grade measurements. The plaintiff will likely argue that ordinary buyers saw the accuracy language and reasonably expected more precise body composition data than the scale could provide.

Why one person can take this to court

The named plaintiff is Victor Maurer, a private individual consumer. That does not mean he is personally funding a solo legal battle against Garmin. This is a proposed class action, which means the case aims to represent a larger group of buyers who allegedly purchased the product under the same kind of marketing claims.

One person’s potential loss might only be the cost of the scale. But if a court certifies a class, the claim can potentially cover many buyers. That is why consumer class actions often start with one named plaintiff but are driven by law firms looking at the broader market.

The case still faces several hurdles. Garmin could seek dismissal. The plaintiff would also need to clear the class certification stage if the case gets that far. Many consumer class actions settle, narrow or disappear before trial, so this should not be treated as a guaranteed win for the plaintiff.

Still, the filing taps into something many smart scale users already suspect. Weight readings are one thing. Body fat percentage, muscle mass and body water are another. Those numbers look precise on a screen, but the technology behind them often works more like an estimate engine than a measurement tool.

Source: Case details checked against PacerMonitor, Law360 and Singletracks. The complaint was filed on May 29, 2026 in the Northern District of Illinois as Maurer v. Garmin International, Inc. et al, case number 1:26-cv-06389.

The post Garmin sued over Index S2 smart scale accuracy claims appeared first on Gadgets & Wearables.

The idea is simple enough. Instead of buying a generic red light device and guessing where to point it, for how long and how often, Photon tries to turn the whole thing into a more structured routine.

A recovery gadget, not another wearable

Photon is a handheld red light therapy gadget, rather than a wearable in the usual sense. It weighs 600g, measures 14.5 × 9.5 × 3.7cm, so not too big, and uses a white matte body with 12 dual-chip LEDs inside.

The device outputs both 660nm visible red light and 850nm near-infrared light. Ultrahuman says the first is aimed more at skin tone, texture and firmness, while the second reaches deeper into muscle and joint tissue. That gives Photon a broader pitch than a simple beauty gadget, even though some of the claims clearly overlap with the skin care world.

There is also a practical side to the hardware. Photon has a 6,000mAh battery, USB-C charging and a claimed six 10-minute sessions from a charge. Charging takes around 3 to 4 hours, so this is more of a home recovery tool than something most people will throw into a gym bag every day.

The app is the real angle

The interesting part is not just the light. Plenty of red light panels, masks and handheld devices already exist. And many of them are cheaper. Photon’s differentiator is the Photon Protocol PowerPlug inside the Ultrahuman app.

This gives users a daily plan showing where to use the device, when to use it, how far to hold it from the body and why that protocol has been suggested. For Ultrahuman Ring users, those recommendations can take recovery, sleep and activity data into account. That makes the product feel less random than a normal red light therapy gadget.

Ultrahuman already has a strong base in passive tracking through the Ring, but Photon pushes it toward active intervention. The Ring tells you how your body looks from the data. Photon then becomes one of the tools the app can point you toward when recovery looks a bit off.

Simple use, familiar claims

Using Photon looks straightforward. Ultrahuman says users should hold it 2 to 6 inches from bare skin, press the power button for 2 seconds and let it run through a 10-minute session. The device shuts off automatically once the session ends.

The company recommends 2 to 4 inches for areas such as legs, back and shoulders, and 4 to 6 inches for the face or neck. The page also mentions adherence tracking, streaks, weekly insights and guardrails around underuse or overuse.

Why this fits Ultrahuman’s direction

Photon also says something about where Ultrahuman wants to go next. The company already has the Ring as its main data product, but red light therapy moves it into a more crowded and more subjective recovery category.

That makes the app layer important. Without the protocols, Photon risks looking like another handheld red light device in a market that already has plenty of cheaper options. With the protocols, Ultrahuman can at least argue that it is adding structure to a habit many people still use in a fairly random way.

Shipping is listed from July 15 onwards, with the device priced at $250 including tax. The box includes Photon, a power adapter and a travel case.

The post Ultrahuman Photon brings red light therapy into its recovery ecosystem appeared first on Gadgets & Wearables.

This is not a feature you can turn on today. But it is one of the more interesting examples of where smartwatch health tracking could go next, especially for people who deal with sudden fainting episodes and the injury risk that comes with them.

Why fainting prediction is different

Vasovagal syncope happens when heart rate and blood pressure drop suddenly, often after stress, pain, heat, standing or sitting for too long or another trigger. The episode itself usually passes quickly, but the fall can be the real problem.

That is why a few minutes of warning could be useful. It could give someone enough time to sit down, lie down or call for help before losing consciousness.

Samsung says up to 40 percent of people experience vasovagal syncope at some point in life. It also says around one third experience repeat episodes, which makes this less niche than it might sound at first glance.

What the study actually showed

The research team studied 132 patients with suspected vasovagal syncope during induced fainting tests. They used Galaxy Watch6 to collect biosignals through the optical PPG sensor, then analysed heart rate variability using an AI model.

The model predicted impending fainting episodes up to five minutes in advance. Samsung says the result came with 84.6 percent accuracy, 90 percent sensitivity and 64 percent specificity.

That mix is worth reading carefully. High sensitivity means the system caught most upcoming episodes. The lower specificity means false alerts remain an issue, which would need work before this could become a polished consumer warning system.

Why Galaxy Watch6 is the interesting part

The study used a commercial smartwatch rather than a lab-only device. That is the key point here, because it suggests common wrist hardware may already capture enough signal to support this kind of prediction with the right algorithm.

That does not mean every Galaxy Watch6 suddenly becomes a fainting detector. It means Samsung and its clinical partners have shown that the raw data from the watch can support the concept under controlled study conditions.

There is also a practical angle. Smartwatches already sit on the wrist all day, so a warning system like this would not need users to wear a specialist device if the feature ever reached real-world deployment.

Still a research result, not a finished feature

Samsung is framing the work as part of a shift from post-event care to preventive health. That is fair enough, but there is a long gap between a clinical study and a consumer feature that people can rely on.

The next steps would likely involve larger studies, real-world testing and regulatory questions. False alerts would also need careful handling, because a fainting warning that triggers too often could become something users ignore.

Still, this is a strong direction for smartwatch health tech. Many wearable features track what has already happened, while this points toward watches that warn before something happens.

The post Samsung wants your Galaxy Watch to warn you before you faint appeared first on Gadgets & Wearables.

Selected users will be able to buy BodyScan 2 weeks ahead of the global release. They will also be asked to share feedback through surveys and may join 30 minute calls with Withings’ Product and Marketing teams.

The company says participants who complete at least 80 percent of the surveys will receive an exclusive reward. The program is Europe only for now, although Withings says BodyScan 2 will soon be available in the US as well. If you want in, you can apply via this link.

BodyScan 2 is moving closer to launch

The company says participants will receive final, production ready hardware, so this does not appear to be a prototype trial. The remaining work seems to be around firmware, feature activation and real world feedback before the wider rollout.

BodyScan 2 was announced earlier this year as Withings’ next flagship health scale. It is designed to go beyond weight and body composition, with a 90 second scan and a wider set of health metrics.

That includes cardiovascular and metabolic tracking, along with longer term trend features such as Health Trajectory. The device continues the idea of a smart scale as a home health station rather than just a weight tracker.

Early users may shape the final experience

The Insider Program should help Withings clean up the final experience before launch. That probably means checking how reliably the scans work, how clearly the app explains results and whether the firmware behaves properly in daily use.

That is important because BodyScan 2 is trying to do a lot. More metrics only help if users understand what changed and what it means over time. Withings will need the software layer to be as clear as the hardware pitch.

The 500 person limit also keeps the rollout controlled. Withings gets real feedback from engaged users, while buyers get the device before everyone else. It is a practical middle step before the global launch.

A wider release now looks close

Withings previously said BodyScan 2 would arrive in 2026, and this Insider Program suggests the launch window is now tightening. Europe gets the first early access route, while the US is expected to follow soon.

The product still needs to prove that users want this much health tracking from a scale. But the direction is clear. Withings is pushing BodyScan 2 as a more complete home health device, and this early access program looks like the final test before it lands properly.

The post Withings BodyScan 2 early access opens in Europe with 500 spots appeared first on Gadgets & Wearables.

You know the feeling. You’ve woken up feeling strangely worse after what should have been a full night’s sleep. Well, something like this can help. The company is positioning it as the final piece of its “Sleep, by Design” platform. It sits alongside Sleep Assist for falling asleep and Deep Sleep Boost for supporting slow-wave sleep.

A smarter way to wake up

The idea here is simple. But the technology behind it is more interesting than the typical smartwatch-style smart alarm. Rather than estimating sleep stages from movement or heart rate, Muse is using EEG data directly from the headband.

That matters because the whole point of a smart alarm is timing. If you are being woken at the wrong point in your sleep cycle the grogginess can linger well into the morning. Muse says Smart Wakeup continuously monitors brain activity during your chosen wake window and starts a gradual audio alarm the moment it detects lighter sleep. If that moment does not arrive, it still wakes you at the latest set time.

That direct EEG approach is one of the things that stood out to me in my hands-on review of the Muse S Athena. The device’s brain visualisation tools and signal quality were already among its strongest points. So this feels like a natural extension of what the hardware is already good at.

The data behind it

Muse says the feature was developed using an internal study based on around 6,200 nights of sleep data. Some 1300 users in total were looked at, with each session paired to morning mood ratings.

The most interesting takeaway is that sleep duration still matters far more than anything else. In other words, this is not being presented as a fix for poor sleep habits. But for nights where users already got seven or more hours with good sleep efficiency, waking during lighter sleep was linked with noticeably better morning mood.

That feels believable. Anyone who tracks sleep regularly will know that seven hours can feel very different depending on when the alarm hits. Some mornings you wake naturally a few minutes before it goes off and feel clear-headed. Other mornings the same alarm time feels brutal.

Muse’s point is that the timing of your sleep stages shifts from night to night. Travel, stress, schedule changes and even minor routine differences can move REM and lighter sleep periods around, which means a fixed 7am alarm does not always hit the same sleep stage.

What comes next

The company is already talking about where this platform goes next in 2026, and this is where it gets especially interesting. Planned additions include waking once a recovery target has been met, a mode designed to wake users during REM for dream recall, and guided audio layered into the transition from sleep to wakefulness.

Some of that does stray into more speculative territory, but Smart Wakeup itself feels grounded and genuinely useful. Based on my experience with the Muse S Athena, this is exactly the kind of feature that makes sense for the platform. It builds on the headset’s clinical-style EEG strengths rather than trying to imitate what smartwatches are already doing.

Subscribe to our monthly newsletter! Check out our YouTube channel.

And of course, you can follow Gadgets & Wearables on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.

The post Muse Smart Wakeup uses EEG to time your morning alarm appeared first on Gadgets & Wearables.

On paper, it sounds like another health dashboard. It is not really that. The more interesting part is that it tries to sit on top of everything you already use and make sense of it.

Less dashboards, more asking questions

Most health apps still expect you to dig through charts. You scroll, tap around, maybe spot a trend if you are paying attention.

This flips that around. You just ask. And presumably, its deeper that what you get on some AI chat features that you get in some fitness apps. Plus you can link up different sources.

For example, you can ask how your sleep has changed recently. Or whether your resting heart rate is trending up. Or how your activity lines up with recovery. The system pulls data from various places and gives you a straight answer.

That might sound simple, but it changes how you use this stuff. Instead of trying to interpret graphs yourself, you get something closer to an explanation.

There is also this idea of “health memory”. Basically, the system builds up a profile of you over time.

It keeps track of past data, previous questions and whatever you have uploaded. That context feeds into future answers, so things should get more relevant the longer you use it.

Pulling everything into one place

All of this only works if the data is actually there. So integrations are a big part of it.

You can connect Apple Health, Fitbit and Withings at launch. On top of that, you can bring in lab results, prescriptions and other records, or just upload files yourself.

There is some plumbing behind the scenes to make this work. Medical records come through a partner system, while fitness apps connect through APIs. You still have to approve everything manually, so it is not exactly plug and play. But once it is set up, the idea is that everything sits in one place.

Our takeaway

Strip away the features and this is really about control. Right now, your health data sits inside separate ecosystems. Each one gives you its own view, its own logic and its own limits. Perplexity is trying to sit above that and give you a single way to interact with everything.

That only works if the answers are actually better than what you get inside those apps. If it just repackages the same insights in a different format, there is not much value there. The whole pitch depends on whether it can connect things in a way the original platforms do not.

There is also a dependency problem. It does not own the data or the hardware. It relies entirely on other platforms continuing to provide access. That puts a ceiling on how far it can go, especially if those ecosystems decide to keep more of their insights locked in.

So the idea is clear. One interface, all your data. But will it tell you something new, or just save you a few taps? If it is just the second, it will not really be that useful. The real value is in connecting dots you would not spot yourself, and that is where things are heading. AI insights are the future.

Subscribe to our monthly newsletter! Check out our YouTube channel.

And of course, you can follow Gadgets & Wearables on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.

The post Perplexity Health takes aim at messy fitness data appeared first on Gadgets & Wearables.

Huawei diabetes risk alerts

Huawei’s latest smartwatch update aims to offer early warning signs of diabetes risk, using optical heart rate sensors and a new app. Rather than attempting direct blood sugar measurements, it focuses on vascular and nerve signal patterns linked to long-term glucose problems.

The company is positioning the new feature in the wellness camp. Needless to say, this is not a diagnostic tool, nor is it being framed as a replacement for lab tests. Instead, the Diabetes Risk app is pitched as a prompt for further evaluation. If you land in the Medium or High category, Huawei recommends speaking with a doctor.

The core of the approach relies on PPG, the same tech used to track heart rate. Huawei’s system looks for long-term changes in those signals. Specifically, it’s tracking variations that could point to diabetes-related microvascular or neuropathic effects. These may develop silently over time and subtly affect how light is absorbed or reflected under the skin.

Huawei also leans on some scientific context here. At the Dubai launch, the company referenced studies suggesting shared genetic factors between resting heart rate and diabetes, along with vascular and nerve damage altering PPG waveforms. The idea is that these slow shifts in signal pattern, captured during daily wear, might be enough to flag emerging issues.

This is a passive feature. You wear the watch as usual, and over the course of three to 14 days, it collects enough data to assess your risk. The app then categorises results into Low, Medium or High, with only the latter two triggering a suggestion to seek medical input. The company makes clear it isn’t diagnosing anything.

The rollout starts with the Huawei GT 6 Pro. An over-the-air update activates the functionality. More models are expected to get support, though no full timeline has been confirmed yet. Users don’t need to trigger anything manually once the update is installed. Just wearing the device is enough for the system to start logging.

Professor Jiguang Wang, Director of the Shanghai Institute of Hypertension, joined Huawei on stage for the unveiling. He has worked with the brand before, including on the WATCH D series with its inflatable wrist-cuff for blood pressure readings. At the event, he spoke about the growing potential of PPG-based insights for population health, especially in early detection.

Garmin has something different in mind

It’s worth noting how this differs from what Garmin has proposed. Garmin’s recent patent goes after HbA1c estimation, a long-term blood glucose marker typically requiring a lab test. That system uses multi-wavelength light sensors and spectral analysis to derive estimated values over time. Huawei, by contrast, isn’t trying to quantify anything directly. It’s spotting trends that might correlate with risk, not estimating specific blood sugar markers.

For now, Huawei’s feature avoids regulatory complications by focusing on general wellness. It may also sidestep the accuracy and reliability hurdles that come with trying to deliver clinical-grade data. But as sensor quality improves and algorithms mature, the line between wellness and diagnostic tech is becoming harder to draw.

via Gulfbusiness.com

Subscribe to our monthly newsletter! Check out our YouTube channel.

And of course, you can follow Gadgets & Wearables on Google News and add us as your preferred source to get our expert news, reviews, and opinion in your feeds.

The post Huawei adds diabetes risk alerts to GT 6 Pro smartwatches appeared first on Gadgets & Wearables.